Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 6/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5944582 | 0.84 | ACHE (0.39) | ACHE | |
| SCHEMBL2579969 | 0.70 | — | — | |
| SCHEMBL11255695 | 0.69 | ACHE (0.40) | ACHE | |
| SCHEMBL20128354 | 0.65 | TP53 (0.32) | — | |
| SCHEMBL2791561 | 0.64 | — | — | |
| SCHEMBL31547606 | 0.64 | — | — | |
| SCHEMBL20128350 | 0.63 | KCNH2 (0.37) | — | |
| SCHEMBL8883116 | 0.62 | ACHE (0.38) | ACHE | |
| Hydrochloric Acid SCHEMBL9313820 | 0.62 | LMNA (0.41) | ACHE | |
| SCHEMBL4719848 | 0.61 | NQO2 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1435953-A4 | ANTIVESICANT COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | US ARMY MED RES MAT COMMAND (US) | 2005-05-04 | — | — | EP | claimed |
| EP-1435953-A1 | ANTIVESICANT COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | U.S. Army Medical Research and Materiel Command (US) | 2004-07-14 | — | — | EP | claimed |
| US-20030055090-A1 | Antivesicant compounds and methods of making and using thereof | LG DISPLAY CO., LTD. (KR) | 2003-03-20 | — | — | US | claimed |
| WO-2003011292-A1 | ANTIVESICANT COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND (US) | 2003-02-13 | — | — | WO | claimed |
| EP-1435953-A4 | ANTIVESICANT COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | US ARMY MED RES MAT COMMAND (US) | 2005-05-04 | — | — | EP | disclosed |
| EP-1435953-A1 | ANTIVESICANT COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | U.S. Army Medical Research and Materiel Command (US) | 2004-07-14 | — | — | EP | disclosed |
| US-6664280-B2 | For decontaminating an area exposed to a vesicant agent; for therapy of prophylaxis or inhibiting injuries induced by a vesicant agent, such as bis-2-chloroethylsulfide (HD) | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2003-12-16 | — | — | US | disclosed |
| US-20030055090-A1 | Antivesicant compounds and methods of making and using thereof | LG DISPLAY CO., LTD. (KR) | 2003-03-20 | — | — | US | disclosed |
| WO-2003011292-A1 | ANTIVESICANT COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND (US) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055090-A1 | Antivesicant compounds and methods of making and using thereof | MGMT, C9, DUS2 | ACHE 974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.